Gastrointesinal Drugs News：胃腸薬関連ニュースサービス
Gastrointestinal Drug News
|発行||Espicom Business Intelligence||商品コード||66834|
These days we all suffer from information overload. To overcome this problem, the Gastrointestinal Drug News service focuses specifically on GI drugs, delivering the information you need in a timely, flexible and convenient format.
Long gone are the days when the GI market was dominated by H2 antagonists and PPIs with the focus very much on conditions of the upper GI tract. The treatment of GORD continues to be a growth market, but now growing clinical awareness and improving rates of diagnosis are seeing conditions such as IBD (ulcerative colitis, Crohn' s disease) and IBS take centre stage in future plans - indeed, many feel that the potential patient population for these conditions is only now beginning to be recognised.
For pharmaceutical company executives, researchers and commercial managers, this sector is taking an important role in the industry' s plans; staying in touch with the latest twists and turns, however, is another matter. That is why this new, daily-updated online information service is essential.